Inclusion Criteria:
* Age 18-75 years.
* Diagnosis of AIHA according to established Chinese or international criteria, including warm AIHA, mixed AIHA, cold agglutinin disease, or Evans syndrome.
* Refractory to multiple lines of therapy, meeting all of the following: HGB \<100 g/L with evidence of hemolytic anemia; Prior treatment with ≥2 immunosuppressive therapies, including a CD20 monoclonal antibody; Glucocorticoid treatment for ≥3 months, unless contraindicated or intolerable; Adequate prior CD20 monoclonal antibody treatment (≥4 doses of 100 mg or 375 mg/m², or 2 doses of 1,000 mg).
* ECOG performance status ≤2.
* Participants and their partners agree to use effective contraception from informed consent through 1 year after study treatment.
* Written informed consent must be obtained before any study-specific screening procedures.
Exclusion Criteria:
* Diagnosed lymphoproliferative malignancy.
* Secondary AIHA caused by drugs or infection.
* Congenital immunodeficiency or other inherited or acquired hemolytic disorders.
* Prior organ or hematopoietic stem cell transplantation.
* New thrombotic events or organ infarction within 6 months before enrollment.
* Prior BCMA-targeted therapy within 6 months before enrollment.
* Any of the following prior treatments within the specified washout periods: Anti-CD20 monoclonal antibody within 12 weeks; Sutimlimab or other approved biologic therapy within 5 half-lives; Plasma exchange within 4 weeks; Splenectomy within 12 weeks.
* Any of the following cardiovascular conditions: LVEF ≤45%; Active cardiac disease or NYHA class III/IV heart failure; Clinically significant arrhythmia requiring treatment, except atrial fibrillation or paroxysmal supraventricular tachycardia; QTc ≥450 ms in males or ≥470 ms in females; Myocardial infarction, coronary artery bypass grafting, or coronary stent placement within 6 months; Other clinically significant cardiac disease considered unsuitable by the investigator.
* Unstable systemic disease, including severe hepatic or renal disease requiring treatment.
* History of another primary malignancy within 5 years before screening, except adequately treated non-melanoma skin cancer, carcinoma in situ, or other malignancies without recurrence for ≥5 years.
* Major surgery within 4 weeks before screening if considered unsuitable for enrollment by the investigator.
* Uncontrolled active fungal, viral, bacterial, tuberculosis, or other infection, or infection requiring intravenous antimicrobial therapy.
* Active or clinically significant HBV, HCV, HIV, or syphilis infection
* Live-virus vaccination within 4 weeks before enrollment.
* Participation in another interventional clinical study within 5 half-lives of the investigational treatment before screening, or planned use of another investigational treatment during this study.
* Pregnant or breastfeeding women.
* Psychiatric disorders, impaired consciousness, or central nervous system disorders, including a history of epilepsy or Parkinson's disease.
* Known hypersensitivity to any component of F182112.
* Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.
